Cart
sales@molnova.com
SMARCA-BD ligand 1 for Protac
CAS No. 1997319-92-2
SMARCA-BD ligand 1 for Protac( —— )
Catalog No. M33230 CAS No. 1997319-92-2
SMARCA-BD ligand 1 for Protac is a compound that binds to SMARCA2, the BAF ATPase subunit, utilizing Protac technology to degrade SMARCA2.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 140 | In Stock |
|
| 10MG | 227 | In Stock |
|
| 25MG | 385 | In Stock |
|
| 50MG | 531 | In Stock |
|
| 100MG | 724 | In Stock |
|
| 200MG | 986 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSMARCA-BD ligand 1 for Protac
-
NoteResearch use only, not for human use.
-
Brief DescriptionSMARCA-BD ligand 1 for Protac is a compound that binds to SMARCA2, the BAF ATPase subunit, utilizing Protac technology to degrade SMARCA2.
-
DescriptionSMARCA-BD ligand 1 for Protac is a compound that binds to the BAF ATPase subunits SMARCA2, and used for degrading SMARCA2, based on PROTAC.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetEpigenetic Reader Domain
-
RecptorEpigenetic Reader Domain
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1997319-92-2
-
Formula Weight271.32
-
Molecular FormulaC14H17N5O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESNC1=C(C=C(N=N1)C2=C(O)C=CC=C2)N3CCNCC3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Farnaby W, et al. BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design. Nat Chem Biol. 2019 Jul;15(7):672-680.?
molnova catalog
related products
-
PBRM1-BD2-IN-8
PBRM1-BD2-IN-8 (compound 34) is a potent PBRM1 Bromodomain inhibitor with PBRM1-BD2 Kd of 4.4 μM, PBRM1-BD2 IC50 of 0.16 μM, and PBRM1-BD5 Kd of 25 μM; PBRM1-BD2-IN-8 shows anti-cancer activity.
-
Diflunisal
Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs.
-
C-82
C-82 is a specific CBP/β-catenin antagonist. It inhibits the binding between β-catenin and CBP and increases the binding between β-catenin and p300.
